Seeking Alpha

Bio Bull's  Instablog

Bio Bull
Send Message
I have been occasionally investing, as my personal time and money permit, via long positions over the course of 10 years. I don't work for a brokerage firm, and I'm not a professional trader. My interest has been predominantly within the biotechnology and energy sectors. I'm a CPA licensed in... More
View Bio Bull's Instablogs on:
  • Evoke Article Submitted!

    I've submitted my detailed article on Evoke Pharma. I look forward to everyone reading it and hopefully finding it an interesting value in the biotech market. Thanks all!

    Disclosure: I am long EVOK, .

    Additional disclosure: Please use my article for information only and conduct your own due diligence when making investment decisions.

    Jan 12 11:36 PM | Link | 2 Comments
  • Evoke Pharma (EVOK) Article Coming Soon To Seeking Alpha!

    Hopefully everyone has a chance to read my Neuralstem article published on Seeking Alpha earlier today. I'm putting the finishing touches on my in-depth article for a company called Evoke Pharma which is one of my favorite stocks in 2014. I'll provide some highlights.

    Evoke Pharma (NASDAQ:EVOK) went public in September 2013 at $12 per share. Since the IPO, the share price has ranged from $6.75 to $14.25. The current share price is $8 which seems to be a resistance point at which the stock generally stays around. In general, in the past month and a half, the share price has slid due to low volume and lack of coverage. Part of the problem is that the Phase 2B was completed pre-IPO and thus many investors are simply unaware of Evoke.

    Evoke has a low float. There are approximately 6.1 million shares in total, and 6.8 million fully diluted, but only 2.4 million shares are freely tradeable without restriction. This means shares are likely to rise, fast, during 2014 as investors accumulate shares and Phase 3 launches which is expected to occur soon.

    Evoke is aiming to treat a condition in women known as diabetic gastroparesis in which a patient's stomach has difficulty properly emptying food which can lead to feeling bloated, feelings of pain, and vomiting. Only one product is approved by the FDA currently, oral and intravenous forms of metoclopramide. Evoke is relatively safe for a biotech because their product is simple... they are developing a nasal version of metoclopramide to treat the very same condition! Metoclopramide has been proven effective in treating diabetic gastroparesis. The Phase 2B produced very positive results. Evoke need only complete the Phase 3 study and a QT study to show no cardiac effects (which metoclopramide is not known to have) in order to seek FDA approval which seems highly likely.

    Why a nasal version of metoclopramide? Evoke believes the health community is aware of the problem of using oral medications to treat a patient that has problems with the stomach. For example, if symptoms often involve vomiting, the patient may vomit out the oral metoclopramide and not receive relief of their diabetic gastroparesis symptoms.

    Evoke has price targets of $19 and $60. Annual sales are projected at $230 million by one analyst and $400 million by another analyst. Even at the lowest projection, if they were to sell the company during 2014 at the price of only one year of projected sales ($230 million), the share price could potentially quadruple.

    I have further details captured in my article but hopefully this gives you a sense of the opportunity that I believe exists for Evoke Pharma. You can learn more about them by checking their website below:

    http://www.evokepharma.com

    I've nearly completed the article. I anticipate it being published sometime on Monday (1/13) or Tuesday of next week which also happens to be when Evoke will be presenting at a biotech conference in San Francisco. If Evoke successfully demonstrates how large their potential market is and why it should easily succeed, shares may benefit. In concluding, Evoke appears to be a single trial away from FDA approval, with little risk of trial failure, and it should be able to generate a large gain from the current share price as 2014 progresses.

    Thanks all!

    Disclosure: I am long EVOK, .

    Jan 07 3:36 PM | Link | 10 Comments
  • New Neuralstem Article Is Imminent!

    I'll be delivering a Neuralstem (NYSEMKT:CUR) article sometime on Monday or Tuesday. I've been wanting to revisit Neuralstem and, in particular, discuss the NSI-566 Phase 2 trial for ALS being conducted currently. This isn't an in-depth article like my previous one. Instead it is more of an update.

    My article will recap some useful background information on the trial before explaining why I like some of the information coming from the on-going Phase 2 including comments from a patient currently in the trial. I plan to explain why I believe the trial is poised for a successful outcome.

    I do not touch on NSI-189 very much, but I do want to give any readers fair warning that those results are expected sometime soon as well. I believe the Phase 2 ALS trial will continue to generate most of the excitement for Neuralstem in 2014 and that the NSI-189 results could only have a benefit on the share price.

    Check back on Tuesday or Wednesday for my blog updates regarding my next in-depth article. I'm putting the finishing touches on it and conducting edits and reviews. I plan to submit the article the following week, around 1/13, and I will go into detail in my blog on Tuesday/Wednesday in case you're interested.

    Thanks all! Happy New Year and hopefully we all have a great 2014!!!

    Disclosure: I am long CUR, .

    Jan 05 10:51 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

  • $CUR Interview with Richard Garr posted. http://bit.ly/1wefShi Lot of interesting notes here.
    Sep 8, 2014
  • $CUR Another analyst getting on board with Neutral rating. http://bit.ly/1lNLB7Y
    Sep 8, 2014
  • $CUR Picking up momentum! Garr to present next week. Of note is that we may hear plans on the Phase 2 trial for NSI-189, NFL alumni trial?
    Sep 5, 2014
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.